![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Sunday, August 02, 2015 8:53:17 PM
I think the better question to ask IPCI is if they are developing two different Rexista formulations. For the sake of differentiation, let’s refer to them as Rexista Legacy and Rexista PODRAS. Rexista Legacy is a mechanical barrier ADF 12 hour oxycodone formula with successful Phase 1 results and is likely undergoing Human Abuse Liabilty studies at this time. The company says it has been informed by FDA that Rexista Legacy may be able to skip Phase 3 and therefore will be ready for NDA submission within 6-12 months. The company would use revenue from FDA-approved Rexista Legacy as a non-dilutive source of funding to research and develop Rexista PODRAS, an augmented formulation of Rexista Legacy in which preclinical studies suggest it could possibly reduce oral abuse and may prevent oral overdose. Due to this unique characteristic, Rexista PODRAS fulfills an unmet medical need and was granted Fast Track status by FDA.
In my opinion, Rexista Legacy may be producing revenue within 12-18 months, and those revenues will be used to develop Rexista PODRAS. For whatever reason, the company has not been forthright about the two different Rexista development programs. If they used my terminology, the recent PR's would read as below (obviously, edits in red are added by me).
August 28, 2014
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology
Preclinical studies of Rexista™ (PODRAS) suggest that, unlike other third-party abuse-deterrent oxycodone products, if more tablets than prescribed are deliberately or inadvertently swallowed, the amount of drug active released over 24 hours may be substantially less than expected, even possibly approaching zero. However, if the prescribed number of pills is swallowed, the drug release should be as expected.
March 30, 2015
Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) (Legacy) Oxycodone XR Tablets, and files an IND for Rexista(TM) (Legacy) Oxycodone XR
Rexista™ (Legacy) Oxycodone XR
The Company recently submitted an Investigational New Drug Application ("IND") to the United States Food and Drug Administration ("FDA") for Rexista™ (Legacy) Oxycodone XR in anticipation of the commencement of Phase III clinical trials. Planning has begun for the Phase III trials that will examine the efficacy and safety of Rexista™ (Legacy) Oxycodone XR in individuals with chronic low back pain.
May 21, 2015
Intellipharmaceutics Intends to Accelerate its Rexista(TM) (Legacy) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
The Company believes the FDA notification is significant as it provides a basis for an accelerated development plan for its Rexista™ (Legacy) Oxycodone XR product candidate, without the need for more costly and time-consuming Phase III studies. The Company intends to file a New Drug Application ("NDA") for Rexista™ (Legacy) Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets with the FDA within the next 6 to 12 months, although no assurance to this effect can be given. Further, there can be no assurance that the FDA will ultimately approve the NDA for sale of Rexista™ (Legacy) Oxycodone XR in the U.S. market, or that it will ever be successfully commercialized.
May 26, 2015
FDA Grants Fast Track Designation for Intellipharmaceutics Rexista(TM) (PODRAS) Oxycodone XR
In March 2015, the Company requested Fast Track designation for its novel, and potentially first-in-class, Rexista™ (PODRAS) Oxycodone XR abuse deterrent oxycodone hydrochloride extended release tablets incorporating its PODRAS™ technology platform. A basis for the request was that Rexista™ (PODRAS) Oxycodone XR has the potential to address an unmet medical need, namely the prevention, deterrence or reduction of the abuse of oxycodone HCl extended release solid oral dosage forms involving the deliberate or inadvertent oral ingestion of more intact pills or tablets than prescribed to achieve a feeling of euphoria. This is a very common and serious form of drug abuse.
"There are three kinds of lies: lies, damned lies, and statistics."
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM